← Leaderboards
Seiko Ikezu
Mayo Clinic Jacksonville
$2,629,396
Attributed
$3,626,497
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2023–25$5M$3.8M$2.5M$1.3M$0
'23
'24
'25
Funding mix
By agency
NIH$3,626,497 · 2
By mechanism
RF1$1,994,202 · 1
R01$1,632,295 · 1
Top collaborators
- Tsuneya Ikezu1 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Owen A Ross$6,984,169
- Leonard Petrucelli$43,938,031
- Lea Tenenholz Grinberg$17,312,791
- Chad A Dickey$4,755,254
- Andrew J Saykin$38,010,806
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposPlayAge MonthsIn VivoPathogenicityPersonsEntorhinal CortexHippocampusInduced Pluripotent Stem CellIn VitroNerve DegenerationNeuropathologyCognitive FunctionPathologicImpaired CognitionComparison ControlAffectBrainMouse ModelBrain TissueAnimal ModelCell LineCellsS Disease
Grant awards (4)
Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimerâs disease$536,795
R01 · FY2025 · AG · contact PI
Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimerâs disease$547,750
R01 · FY2024 · AG · contact PI
Tumor susceptibility gene 101, a new microglial therapy candidate for Alzheimerâs disease to prevent cognitive decline$1,994,202
RF1 · FY2023 · AG · contact PI
Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimerâs disease$547,750
R01 · FY2023 · AG · contact PI